Cargando…

A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance

Coronaviruses (CoVs) encode nonstructural proteins 1–16 (nsps 1–16) which form replicase complexes that mediate viral RNA synthesis. Remdesivir (RDV) is an adenosine nucleoside analog antiviral that inhibits CoV RNA synthesis. RDV resistance mutations have been reported only in the nonstructural pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Grimes, Samantha L., Choi, Young J., Banerjee, Anoosha, Small, Gabriel, Anderson-Daniels, Jordan, Gribble, Jennifer, Pruijssers, Andrea J., Agostini, Maria L., Abu-Shmais, Alexandra, Lu, Xiaotao, Darst, Seth A., Campbell, Elizabeth, Denison, Mark R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470589/
https://www.ncbi.nlm.nih.gov/pubmed/37338298
http://dx.doi.org/10.1128/mbio.01060-23
_version_ 1785099712573997056
author Grimes, Samantha L.
Choi, Young J.
Banerjee, Anoosha
Small, Gabriel
Anderson-Daniels, Jordan
Gribble, Jennifer
Pruijssers, Andrea J.
Agostini, Maria L.
Abu-Shmais, Alexandra
Lu, Xiaotao
Darst, Seth A.
Campbell, Elizabeth
Denison, Mark R.
author_facet Grimes, Samantha L.
Choi, Young J.
Banerjee, Anoosha
Small, Gabriel
Anderson-Daniels, Jordan
Gribble, Jennifer
Pruijssers, Andrea J.
Agostini, Maria L.
Abu-Shmais, Alexandra
Lu, Xiaotao
Darst, Seth A.
Campbell, Elizabeth
Denison, Mark R.
author_sort Grimes, Samantha L.
collection PubMed
description Coronaviruses (CoVs) encode nonstructural proteins 1–16 (nsps 1–16) which form replicase complexes that mediate viral RNA synthesis. Remdesivir (RDV) is an adenosine nucleoside analog antiviral that inhibits CoV RNA synthesis. RDV resistance mutations have been reported only in the nonstructural protein 12 RNA-dependent RNA polymerase (nsp12-RdRp). We here show that a substitution mutation in the nsp13-helicase (nsp13-HEL A335V) of the betacoronavirus murine hepatitis virus (MHV) that was selected during passage with the RDV parent compound confers partial RDV resistance independently and additively when expressed with co-selected RDV resistance mutations in the nsp12-RdRp. The MHV A335V substitution did not enhance replication or competitive fitness compared to WT MHV and remained sensitive to the active form of the cytidine nucleoside analog antiviral molnupiravir (MOV). Biochemical analysis of the SARS-CoV-2 helicase encoding the homologous substitution (A336V) demonstrates that the mutant protein retained the ability to associate with the core replication proteins nsps 7, 8, and 12 but had impaired helicase unwinding and ATPase activity. Together, these data identify a novel determinant of nsp13-HEL enzymatic activity, define a new genetic pathway for RDV resistance, and demonstrate the importance of surveillance for and testing of helicase mutations that arise in SARS-CoV-2 genomes. IMPORTANCE: Despite the development of effective vaccines against COVID-19, the continued circulation and emergence of new variants support the need for antivirals such as RDV. Understanding pathways of antiviral resistance is essential for surveillance of emerging variants, development of combination therapies, and for identifying potential new targets for viral inhibition. We here show a novel RDV resistance mutation in the CoV helicase also impairs helicase functions, supporting the importance of studying the individual and cooperative functions of the replicase nonstructural proteins 7–16 during CoV RNA synthesis. The homologous nsp13-HEL mutation (A336V) has been reported in the GISAID database of SARS-CoV-2 genomes, highlighting the importance of surveillance of and genetic testing for nucleoside analog resistance in the helicase.
format Online
Article
Text
id pubmed-10470589
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-104705892023-09-01 A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance Grimes, Samantha L. Choi, Young J. Banerjee, Anoosha Small, Gabriel Anderson-Daniels, Jordan Gribble, Jennifer Pruijssers, Andrea J. Agostini, Maria L. Abu-Shmais, Alexandra Lu, Xiaotao Darst, Seth A. Campbell, Elizabeth Denison, Mark R. mBio Research Article Coronaviruses (CoVs) encode nonstructural proteins 1–16 (nsps 1–16) which form replicase complexes that mediate viral RNA synthesis. Remdesivir (RDV) is an adenosine nucleoside analog antiviral that inhibits CoV RNA synthesis. RDV resistance mutations have been reported only in the nonstructural protein 12 RNA-dependent RNA polymerase (nsp12-RdRp). We here show that a substitution mutation in the nsp13-helicase (nsp13-HEL A335V) of the betacoronavirus murine hepatitis virus (MHV) that was selected during passage with the RDV parent compound confers partial RDV resistance independently and additively when expressed with co-selected RDV resistance mutations in the nsp12-RdRp. The MHV A335V substitution did not enhance replication or competitive fitness compared to WT MHV and remained sensitive to the active form of the cytidine nucleoside analog antiviral molnupiravir (MOV). Biochemical analysis of the SARS-CoV-2 helicase encoding the homologous substitution (A336V) demonstrates that the mutant protein retained the ability to associate with the core replication proteins nsps 7, 8, and 12 but had impaired helicase unwinding and ATPase activity. Together, these data identify a novel determinant of nsp13-HEL enzymatic activity, define a new genetic pathway for RDV resistance, and demonstrate the importance of surveillance for and testing of helicase mutations that arise in SARS-CoV-2 genomes. IMPORTANCE: Despite the development of effective vaccines against COVID-19, the continued circulation and emergence of new variants support the need for antivirals such as RDV. Understanding pathways of antiviral resistance is essential for surveillance of emerging variants, development of combination therapies, and for identifying potential new targets for viral inhibition. We here show a novel RDV resistance mutation in the CoV helicase also impairs helicase functions, supporting the importance of studying the individual and cooperative functions of the replicase nonstructural proteins 7–16 during CoV RNA synthesis. The homologous nsp13-HEL mutation (A336V) has been reported in the GISAID database of SARS-CoV-2 genomes, highlighting the importance of surveillance of and genetic testing for nucleoside analog resistance in the helicase. American Society for Microbiology 2023-06-20 /pmc/articles/PMC10470589/ /pubmed/37338298 http://dx.doi.org/10.1128/mbio.01060-23 Text en Copyright © 2023 Grimes et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Grimes, Samantha L.
Choi, Young J.
Banerjee, Anoosha
Small, Gabriel
Anderson-Daniels, Jordan
Gribble, Jennifer
Pruijssers, Andrea J.
Agostini, Maria L.
Abu-Shmais, Alexandra
Lu, Xiaotao
Darst, Seth A.
Campbell, Elizabeth
Denison, Mark R.
A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance
title A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance
title_full A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance
title_fullStr A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance
title_full_unstemmed A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance
title_short A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance
title_sort mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470589/
https://www.ncbi.nlm.nih.gov/pubmed/37338298
http://dx.doi.org/10.1128/mbio.01060-23
work_keys_str_mv AT grimessamanthal amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT choiyoungj amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT banerjeeanoosha amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT smallgabriel amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT andersondanielsjordan amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT gribblejennifer amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT pruijssersandreaj amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT agostinimarial amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT abushmaisalexandra amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT luxiaotao amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT darstsetha amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT campbellelizabeth amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT denisonmarkr amutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT grimessamanthal mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT choiyoungj mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT banerjeeanoosha mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT smallgabriel mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT andersondanielsjordan mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT gribblejennifer mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT pruijssersandreaj mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT agostinimarial mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT abushmaisalexandra mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT luxiaotao mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT darstsetha mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT campbellelizabeth mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance
AT denisonmarkr mutationinthecoronavirusnsp13helicaseimpairsenzymaticactivityandconferspartialremdesivirresistance